Neko Health Raises $700 Million For US AI Body-Scan Clinics

$700 million in new Series C funding will take Neko Health's AI body-scan clinic model into the United States, starting with New York, AI News reported.

The preventive-screening company combines medical imaging, blood tests, proprietary sensors and clinician review in a clinic visit built around early health-risk detection.

Lightspeed Venture Partners led the round and O.G. Venture Partners co-led it, the article states.

Atomico, General Catalyst and Lakestar returned as investors.

Liberty City Ventures, Positive Sum and BDT & MSD joined as new backers.

Funding Brings Disclosed Capital Above $1 Billion

The new round brings the company's disclosed capital raised since 2023 to more than $1 billion, the article indicates.

Earlier fundraising included a $65 million Series A in 2023 and a $260 million round in January 2025, the article says.

David Ofer of O.G. Venture Partners is expected to join the board, subject to regulatory approval.

The financing also included investments from Mark Zuckerberg and Priscilla Chan, Maria Sharapova, will.i.am and Thierry Henry.

Existing individual investors include Alexis Ohanian and Zoë Saldaña.

The funding is intended to support clinics in New York and other U.S. cities.

A New York waitlist is open.

Additional U.S. locations and the detailed rollout schedule remain outside the cited public materials.

Neko Health Scan Combines Imaging, Blood Tests And Clinician Review

Neko Health's clinics use body-scan hardware, blood testing, AI analysis and custom medical equipment.

The article describes the service as screening customers for potential signs of skin cancer, cardiovascular disease and diabetes.

Neko Health describes the assessment as a 60-minute, non-invasive and radiation-free visit.

According to Neko Health's materials, the visit includes an electrocardiogram, arterial measurements, body-composition analysis and more than 2,000 high-resolution skin images, with blood samples processed at the clinic so results can be reviewed during the same visit.

Results are discussed in person with a medical professional.

Specialist clinicians, including dermatologists and cardiologists, review findings that require further examination, and the privacy notice tells customers to continue seeing their existing clinicians for diagnosis and treatment.

Existing Clinics Give Pricing And Usage Evidence

The company currently operates eight clinics across the UK and Sweden, the article states.

The clinic list includes two sites in Stockholm, one each in Manchester and Birmingham, and four London locations in Marylebone, Spitalfields, Covent Garden and Victoria.

The article lists a UK scan price of £299 and a Sweden price of 2,750 Swedish kronor.

Neko Health reports completing 100,000 scans since launching the service in 2023, while more than 350,000 people have registered for a scan or joined waitlists.

Three quarters of customers reserve and prepay for a follow-up scan before leaving the appointment, according to Neko Health.

Repeat scans allow clinicians to compare measurements and skin images over time; the source record does not establish that annual screening is the correct interval for every age or risk group.

FDA Clearances Cover Devices, Not The Full Service

FDA records show two internally developed devices cleared through the 510(k) pathway in May 2026.

Derma-2 received clearance for adjunctive telethermography, and Spectrum-2 received clearance for tissue-oxygen-saturation measurements used in cardiovascular assessment.

The regulatory scope is limited to those devices and intended uses.

It is not an FDA approval of the full Neko Health Scan as one screening service.

Updated Derma, Echo and Spectrum devices collect more health data and automate additional parts of the scanning workflow, in the company's account.

Neko Health plans to deploy the devices across its clinics in the coming months.

US Pricing And Clinical Performance Data Remain Undisclosed

U.S. clinics do not currently participate in health-insurance plans, and Neko Health says most services are not covered by a payer.

Customers are expected to pay directly for the initial assessment.

The public record does not include a completed peer-reviewed study validating the full screening service.

A ClinicalTrials.gov-registered study is evaluating the company's multimodal skin-imaging technology for screening and diagnostic-support applications, with skin cancer and Raynaud's phenomenon, and the trial remains ongoing.

Neko Health reports health-outcome figures covering 1,469 returning customers who underwent a second scan roughly a year after the first visit.

Blood-pressure, cholesterol and blood-sugar measures improved in that group.

The company characterised the analysis as non-scientific and uncontrolled.

Completed peer-reviewed validation for the full screening service remains outside the public record.